

CITATION REPORT

List of articles citing

Evidence-based medical review update:
pharmacological and surgical treatments of
Parkinsons disease: 2001 to 2004

DOI: 10.1002/mds.20464

Movement Disorders, 2005, 20, 523-39.

Source: <https://exaly.com/paper-pdf/38386386/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
292	Clinical practice. Diagnosis and initial management of Parkinson's disease. 2005 , 353, 1021-7		227
291	Sleep-related problems of Parkinson's disease. 2006 , 35, 220-8		108
290	Parkinson's disease management strategies. 2006 , 6, 91-9		21
289	Medical management of advanced Parkinson's disease. 2006 , 22, 753-72, v		4
288	Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. 2006 , 45, 109-36		116
287	A randomized trial of deep-brain stimulation for Parkinson's disease. 2006 , 355, 896-908		2015
286	A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. 2006 , 28, 1065-1078		219
285	Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. 2006 , 100, 59-64		15
284	Parkinson's disease and deep brain stimulation. 2006 , 2, 473-487		
283	Tolcapone in the management of Parkinson's disease. 2006 , 2, 709-720		4
282	[Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance]. 2006 , 61, 29-38		5
281	Chapter 6.1 The role of microdialysis in drug discovery: focus on antipsychotic agents. 2006 , 16, 485-511		1
280	Implantation of electrodes for deep brain stimulation of the subthalamic nucleus in advanced Parkinson's disease with the aid of intraoperative microrecording under general anesthesia. 2006 , 59, E1138; discussion E1138		76
279	[Pharmacotherapy and guidelines]. 2006 , 35, 242-8		1
278	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. 2006 , 253, 1633-9		20
277	Non-motor symptoms of Parkinson's disease: diagnosis and management. 2006 , 5, 235-45		1757
276	The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 500-9	7	31

275	Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S290-304	7	651
274	Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. <i>Movement Disorders</i> , 2006 , 21, 2110-5	7	50
273	Chapter 50 Pain in Parkinson's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2006 , 81, 747-60	3	9
272	Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1715-30	4	58
271	Movement Disorders. 2007 , 735-763		4
270	Rasagiline for levodopa-induced motor complications in Parkinson's disease. 2007 ,		
269	Balancing short-term symptom control and long-term functional outcomes in patients with Parkinson's disease. 2007 , 12, 275-86		3
268	Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. <i>Clinical Neuropharmacology</i> , 2007 , 30, 150-68	1.4	41
267	A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. <i>Clinical Neuropharmacology</i> , 2007 , 30, 305-7	1.4	4
266	Trastornos del movimiento (I): conceptos generales. Clasificaci?n de los s?ndromes parkinsonianos. Enfermedad de Parkinson. 2007 , 9, 4719-4729		
265	L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment. 2007 , 13 Suppl 3, S263-7		39
264	2.IS.1. New treatment possibilities with oral Levodopa (Novartis Pharma AG/Orion Corporation). 2007 , 13, S144-S145		
263	2.IS.2.1 Dopamine agonists in controlling motor symptoms âclinical relevance of trials. 2007 , 13, S145		
262	2.IS.2.2 Revised UPDRS-assessment of the broad range of symptoms in Parkinson's disease. 2007 , 13, S145		
261	2.IS.2.3 Depression and Parkinson's disease âThe dopaminergic link. 2007 , 13, S145-S146		
260	Rasagiline. 2007 , 67, 1657-1679		19
259	Approche m?ta-analytique de lâfficacit? en monoth?rapie des agonistes dopaminergiques dans le traitement de la maladie de Parkinson. 2007 , 7, 23-30		1
258	Lifetime proteomic profiling of an A30P alpha-synuclein Drosophila model of Parkinson's disease. 2007 , 6, 3729-38		31

257	Medical management of levodopa-associated motor complications in patients with Parkinson's disease. 2007 , 21, 677-92		141
256	Palliative care in amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. 2007 , 10, 433-57		32
255	Protein expression in a Drosophila model of Parkinson's disease. 2007 , 6, 348-57		50
254	Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. 2007 , 92, 168-80		61
253	Rasagiline: a review of its use in the management of Parkinson's disease. 2007 , 67, 1725-47		55
252	Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. <i>Movement Disorders</i> , 2007 , 22, 179-86	7	223
251	Effect of medical and surgical interventions on health-related quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 757-65	7	61
250	Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. <i>Movement Disorders</i> , 2007 , 22, 1550-5	7	29
249	Levodopa-induced dyskinesias. <i>Movement Disorders</i> , 2007 , 22, 1379-1389	7	378
248	Deep brain stimulation for the treatment of atypical parkinsonism. <i>Movement Disorders</i> , 2007 , 22, 2149-55		71
247	Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. <i>Movement Disorders</i> , 2007 , 22 Suppl 17, S351-7	7	95
246	The patient with Parkinson's disease: part I-treating the motor symptoms; part II-treating the nonmotor symptoms. 2007 , 19, 179-97		21
245	[Depression in Parkinson's disease. Assessment and treatment]. 2007 , 78, 715-27; quiz 728		5
244	Cognitive-behavioral Strategies for Parkinson's Disease: A Report of Three Cases. 2007 , 14, 165-176		9
243	Development of a Patient Questionnaire to facilitate recognition of motor and non-motor wearing-off in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2007 , 114, 211-7	4-3	65
242	Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa. 2007 , 254, 19-26		3
241	Management of levodopa-induced dyskinesias in Parkinson's disease. 2007 , 254, 27-31		2
240	Levodopa-induced dyskinesias and their management. 2008 , 255 Suppl 4, 32-41		53

239	Therapeutic strategies to prevent motor complications in Parkinson's disease. 2008 , 255 Suppl 4, 42-5		8
238	Placebo influences on dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 700-7	7	99
237	Protection against Parkinson's disease progression: clinical experience. 2008 , 5, 210-25		47
236	Dopamine agonists in Parkinson's disease. 2008 , 8, 671-7		30
235	Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. 2008 , 62, 1864-9		68
234	Motor complications in Parkinson disease: clinical manifestations and management. 2008 , 266, 204-15		39
233	The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 2759-72	4	30
232	[Deep brain stimulation and Parkinson's disease]. 2008 , 51, 491-500		
231	Enhancing aromatic L-amino acid decarboxylase activity: implications for L-DOPA treatment in Parkinson's disease. 2008 , 14, 340-51		46
230	Levodopa for the treatment of Parkinson's disease. 2008 , 359, 2468-76		192
229	Medical management of motor fluctuations. <i>Neurologic Clinics</i> , 2008 , 26, S15-27, v		4-5
228	Adverse events from the treatment of Parkinson's disease. <i>Neurologic Clinics</i> , 2008 , 26, S65-83, vi	4-5	18
227	Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. 2008 , 22, 511-21		16
226	Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study. 2008 , 22, 415-22		41
225	The safety of dopamine agonists in the treatment of Parkinson's disease. 2008 , 7, 111-27		5
224	Parkinson's disease: emerging pharmacotherapy. 2008 , 13, 573-91		17
223	Use of Selegiline as Monotherapy and in Combination with Levodopa in the Management of Parkinson's Disease: Perspectives from the MONOCOMB Study. 2008 , 3,		
222	Movement disorders. 2008 , 8, 508-521		

221	Pramipexole in the management of Parkinson's disease. 2008 , 4, 225-235		
220	Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. <i>Clinical Neuropharmacology</i> , 2008 , 31, 261-6	1.4	55
219	Intensive Amplitude-specific Therapeutic Approaches for Parkinson's Disease. 2008 , 24, 99-114		53
218	Anesthesia for Stereotactic Surgery. 2008 , 136-140		
217	COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 1-9 ³⁻¹		47
216	Dorsolateral prefrontal cortex: a possible target for modulating dyskinesias in Parkinson's disease by repetitive transcranial magnetic stimulation. 2008 , 2008, 372125		21
215	A review of ropinirole prolonged release in Parkinson's disease. 2009 , 4, 179-86		24
214	Non-motor off symptoms in Parkinson's disease. 2009 , 24, 311-4		22
213	Identification of the subthalamic nucleus in deep brain stimulation surgery with a novel wavelet-derived measure of neural background activity. 2009 , 111, 767-74		25
212	Deep brain stimulation in Parkinson's disease. 2009 , 2, 20-8		108
211	Levodopa-related wearing-off in Parkinson's disease: identification and management. 2009 , 25, 841-9		61
210	A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. 2009 , 8, 929-37		145
209	Reply. 2009 , 65, 481-481		1
208	Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. <i>Movement Disorders</i> , 2009 , 24, 25-31	7	32
207	Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device. <i>Movement Disorders</i> , 2009 , 24, 551-6	7	114
206	Serotonin and Parkinson's disease: On movement, mood, and madness. <i>Movement Disorders</i> , 2009 , 24, 1255-66	7	114
205	Restless legs syndrome in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2076-80	7	100
204	An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 2121-7	7	6

203	Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD. 2009 , 256 Suppl 3, 280-5		20
202	Cell-based therapies in Parkinson's disease. 2009 , 9, 292-7		14
201	Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats. 2009 , 204, 241-50		43
200	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. 2009 , 16, 1090-9		53
199	Current strategies in the treatment of Parkinson's disease and a personalized approach to management. 2009 , 9, 1781-9		34
198	Neurobiology and treatment of Parkinson's disease. 2009 , 30, 41-7		168
197	Not lost in translation Sensing the loss and filling the gap during regeneration. 2009 , 20, 691-6		10
196	Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. 2009 , 15, 287-94		46
195	Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. 2009 , 18, 1619-31		68
194	Revisi3n cr3tica de la estimulaci3n subtal3mica en la enfermedad de Parkinson. 2009 , 20, 521-532		5
193	What do clinical trials tell us about treating patients?. 2009 , 15 Suppl 3, S34-7		10
192	Role of dopamine receptor agonists in the treatment of early Parkinson's disease. 2009 , 15 Suppl 4, S44-53		48
191	Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2009 , 32, 48-50	1.4	18
190	Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. <i>Clinical Neuropharmacology</i> , 2010 , 33, 5-10	1.4	33
189	Maladie de Parkinson idiopathique: aspects cliniques, diagnostiques et th3rapeutiques. 2010 , 7, 1-30		
188	Soluble and controlled-release preparations of levodopa: do we really need them?. 2010 , 257, S292-7		2
187	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. 2010 , 9, 573-80		382
186	From the cell to the clinic: a comparative review of the partial D3/D4 receptor agonist and 2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. 2010 , 128, 229-73		54

185	Orodispersible sublingual piribedil to abort OFF episodes: a single dose placebo-controlled, randomized, double-blind, cross-over study. <i>Movement Disorders</i> , 2010 , 25, 368-76	7	18
184	Prescribing patterns of antiparkinsonian agents in Europe. <i>Movement Disorders</i> , 2010 , 25, 1053-60	7	18
183	Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1379-90	7	42
182	Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. <i>Movement Disorders</i> , 2010 , 25, 1627-32	7	34
181	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). <i>Movement Disorders</i> , 2010 , 25, 1530-7	7	17
180	The α 2-adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. <i>Movement Disorders</i> , 2010 , 25, 2084-93	7	33
179	How should we treat a patient with early Parkinson's disease?. 2010 , 64, 1210-9		14
178	Therapy of the Motor Features of Parkinson's Disease. 2010 , 34, 252-272		
177	Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. 2010 , 333, 865-73		116
176	Pharmacotherapy in Parkinson's disease: case studies. 2010 , 3, 117-26		3
175	Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology. 2010 , 75, 2021-7		87
174	Parkinsonism and Other Movement Disorders. 2010 , 511-519		
173	Dyskinesias. 2010 , 350-361		3
172	Safinamide in the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2261-8		36
171	Morbo di Parkinson idiopatico: aspetti clinici, diagnostici e terapeutici. 2010 , 10, 1-29		
170	Parkinson's Disease: Definition, Diagnosis, and Management. 2010 , 405-412		3
169	Molecular and clinical prodrome of Parkinson disease: implications for treatment. 2010 , 6, 309-17		132
168	A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. 2010 , 16, 337-47		18

167	Deuterium substitutions in the L-DOPA molecule improve its anti-kinetic potency without increasing dyskinesias. <i>Experimental Neurology</i> , 2010 , 225, 408-15	5-7	17
166	Levodopa in Parkinson's disease: from the past to the future. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 627-35	4	41
165	Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. 2010 , 24, 941-68		79
164	Molecular mechanisms of L-DOPA-induced dyskinesia. <i>International Review of Neurobiology</i> , 2011 , 98, 95-122	4-4	44
163	Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. 2011 , 121, 605-13		9
162	Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease. 2011 , 432-454		
161	Moving forward: advances in the treatment of movement disorders with deep brain stimulation. 2011 , 5, 69		23
160	Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies. 2011 , 267-310		58
159	Slowing of M1 activity in Parkinson's disease during rest and movement--an MEG study. 2011 , 122, 789-95		22
158	Dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. 2011 , 8, 426-33		65
157	Correlates of constipation in people with Parkinson's. 2011 , 17, 106-11		17
156	Treatment of motor symptoms in advanced Parkinson's disease: a practical approach. 2011 , 35, 1795-807		8
155	Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. 2011 , 32, 631-45		29
154	Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling. 2011 , 5, 38		14
153	Neurodegenerative Diseases. 2011 , 435-450		1
152	Priorities in Parkinson's disease research. 2011 , 10, 377-93		317
151	Pramipexole extended release in Parkinson's disease. 2011 , 11, 1229-34		4
150	Pramipexole for the treatment of early Parkinson's disease. 2011 , 11, 925-35		16

149	Pleiotrophin over-expression provides trophic support to dopaminergic neurons in parkinsonian rats. 2011 , 6, 40		20
148	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S2-41	7	397
147	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
146	Knockdown of GAD67 protein levels normalizes neuronal activity in a rat model of Parkinson's disease. 2011 , 13, 188-97		14
145	Dopamine receptors and Parkinson's disease. 2011 , 2011, 403039		50
144	Safety of rasagiline for the treatment of Parkinson's disease. 2011 , 10, 633-43		21
143	Diagnosis and initiation of treatment in Parkinson's disease. 2011 , 121 Suppl 2, 27-36		13
142	Therapies in Parkinson's disease. 2012 , 25, 433-47		141
141	Nonmotor outcomes in Parkinson's disease: is deep brain stimulation better than dopamine replacement therapy?. 2012 , 5, 23-41		20
140	Clinical management of pain and fatigue in Parkinson's disease. 2012 , 18 Suppl 1, S233-6		22
139	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. 2012 , 11, 643-50		37
138	[Levodopa in the treatment of Parkinson disease -- yesterday and today]. 2012 , 46, 63-75		2
137	A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. 2012 , 26, 557-64		18
136	The immunological challenges of cell transplantation for the treatment of Parkinson's disease. 2012 , 88, 320-31		24
135	Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study. 2012 , 35, 159-71		37
134	Medication Management of Parkinson's Disease: Early versus Advanced Stages. 2012 , 4, 209-214		2
133	Novel Molecular Therapeutics in Parkinson's Disease. 2012 , 245-265		2
132	Improved Dynamic Postural Task Performance without Improvements in Postural Responses: The Blessing and the Curse of Dopamine Replacement. <i>Parkinson's Disease</i> , 2012 , 2012, 692150	2.6	9

131	Patient considerations in early management of Parkinson's disease: focus on extended-release pramipexole. 2012 , 6, 49-54		4
130	Quelles thrapeutiques proposer dans la maladie de Parkinson du sujet g? 2012 , 4, 50-55		0
129	Do Parkinson's disease patients disclose their adverse events spontaneously?. 2012 , 68, 857-65		16
128	Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. 2013 , 260, 429-37		20
127	Innovation and translation efforts in wireless medical connectivity, telemedicine and eMedicine: a story from the RFID Center of Excellence at the University of Pittsburgh. 2013 , 41, 1913-25		5
126	Therapeutic stimulation versus ablation. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2013 , 116, 63-71	3	31
125	MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates. 2013 , 66, 355-64		51
124	TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. 2013 , 73, 337-47		33
123	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. 2013 , 43, 151-6		11
122	Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease. 2013 , 66, 53-64		55
121	Rotigotine transdermal patch for the treatment of Parkinson's Disease. 2013 , 27, 81-95		17
120	IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation. 2013 , 3, 123-131		2
119	Depression. 109-118		
118	Sleep disturbances. 192-210		
117	The impact of neuropsychiatric symptoms on quality of life in Parkinson's disease. 255-260		
116	Neuropsychiatric aspects of the on/off phenomenon. 275-284		
115	Efficacy and safety of computer-assisted stereotactic transplantation of human retinal pigment epithelium cells in the treatment of Parkinson disease. 2013 , 37, 333-7		4
114	Review: management of Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 321-40	3.1	39

113	Referral to rehabilitation in Parkinson's disease: who, when and to what end?. 2013 , 71, 967-72		6
112	Dopamine system: manager of neural pathways. 2013 , 7, 854		13
111	Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients. 2014 , 261, 2438-45		17
110	Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. 2014 , 82, 1402-9		32
109	Deep brain stimulation for tremor. 2014 , 32-45		
108	Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1097-107	4	20
107	Therapy for Parkinson's disease: what is in the pipeline?. 2014 , 11, 24-33		18
106	Long-term outcome of subthalamic nucleus deep brain stimulation for Parkinson's disease using an MRI-guided and MRI-verified approach. 2014 , 85, 1419-25		120
105	Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued. 2014 , 28, 455-74		132
104	Mind-body movement therapies for Parkinson's disease. 2014 ,		3
103	Evidence-based treatment of Parkinson's disease. 2015 , 191-208		
102	Synthetic Proteins and Peptides for the Direct Interrogation of β -Synuclein Posttranslational Modifications. 2015 , 5, 1210-27		10
101	Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies. 2015 , 70, 283-93		36
100	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. 2015 , 132, 96-168		282
99	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015 , 21, 1133-44		113
98	History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents. 2015 , 35, 790-848		74
97	Trastornos del movimiento (I): Conceptos generales, clasificaci3n de los s3ndromes parkinsonianos y enfermedad de Parkinson. 2015 , 11, 4415-4426		1
96	Deep brain light stimulation effects on glutamate and dopamine concentration. 2015 , 6, 23-31		5

95	Tourette syndrome deep brain stimulation: a review and updated recommendations. <i>Movement Disorders</i> , 2015 , 30, 448-71	7	191
94	Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease. 175-186		2
93	The pharmacological basis of Parkinson's disease therapy: an overview. 1-4		
92	Monoamine oxidase inhibitors in the management of Parkinson's disease. 23-33		
91	Oral r(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. <i>Movement Disorders</i> , 2016 , 31, 1381-8	7	6
90	Parkinson's disease. 2016 , 188-196		1
89	Advances in dopamine receptor agonists for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1889-902	4	26
88	Deep-brain stimulation of the subthalamic nucleus in the management of Parkinson's disease. 195-205		
87	Advanced stages of PD: interventional therapies and related patient-centered care. <i>Journal of Neural Transmission</i> , 2016 , 123, 31-43	4-3	25
86	Spinal cord stimulation for Parkinson's disease: a systematic review. <i>Neurosurgical Review</i> , 2016 , 39, 27-35; discussion 35	3-9	40
85	Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma. <i>Cancer Medicine</i> , 2017 , 6, 1341-1352	4-8	9
84	Seventy Years with the Globus Pallidus: Pallidal Surgery for Movement Disorders Between 1947 and 2017. <i>Movement Disorders</i> , 2017 , 32, 972-982	7	26
83	Triggered Drug Release and Enhanced Drug Transport from Ultrasound-Responsive Nanoparticles. 2017 , 277-297		1
82	Treatment Strategies in Early Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 132, 345-360	4-1	9
81	Fluorodopa is a Promising Fluorine-19 MRI Probe for Evaluating Striatal Dopaminergic Function in a Rat Model of Parkinson's Disease. <i>Journal of Neuroscience Research</i> , 2017 , 95, 1485-1494	4-4	3
80	Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease. <i>Parkinson's Disease</i> , 2017 , 2017, 8518929	2-6	1
79	International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1248-1266	7	323
78	Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection. <i>Neuroscience</i> , 2018 , 374, 187-204	3-9	10

77	Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT receptor biased agonists. <i>Experimental Neurology</i> , 2018 , 302, 155-168	5.7	15
76	Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: Transdermal polypharmacy to treat Parkinson's disease. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018 , 127, 204-212	5.7	18
75	Levodopa in Parkinson's Disease: Current Status and Future Developments. <i>Current Neuropharmacology</i> , 2018 , 16, 1239-1252	7.6	71
74	Rutin as a Potent Antioxidant: Implications for Neurodegenerative Disorders. <i>Oxidative Medicine and Cellular Longevity</i> , 2018 , 2018, 6241017	6.7	102
73	Parkinson's disease monitoring from gait analysis via foot-worn sensors. <i>Biocybernetics and Biomedical Engineering</i> , 2018 , 38, 760-772	5.7	26
72	Generation of functional dopaminergic neurons from human spermatogonial stem cells to rescue parkinsonian phenotypes. <i>Stem Cell Research and Therapy</i> , 2019 , 10, 195	8.3	9
71	Neuropsychiatric aspects of Parkinson disease psychopharmacology: Insights from circuit dynamics. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2019 , 165, 83-121	3	9
70	Dopamine neuron induction and the neuroprotective effects of thyroid hormone derivatives. <i>Scientific Reports</i> , 2019 , 9, 13659	4.9	5
69	MDS evidence-based review of treatments for essential tremor. <i>Movement Disorders</i> , 2019 , 34, 950-958	7	43
68	Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. <i>Neurologia (English Edition)</i> , 2019 , 34, 143-152	0.4	3
67	Impulse control disorders in Parkinson disease: A cross-sectional study in Morocco. <i>Revue Neurologique</i> , 2019 , 175, 233-237	3	11
66	Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives. <i>Molecular Neurobiology</i> , 2019 , 56, 4799-4811	6.2	17
65	A novel instrumented walker for individualized visual cue setting for gait training in patients with Parkinson's disease. <i>Assistive Technology</i> , 2020 , 32, 203-213	1.5	4
64	Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms. <i>Frontiers in Neuroscience</i> , 2020 , 14, 602697	5.1	22
63	Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020 , 38, 255-267	4.5	19
62	Two-year follow-up results of magnetic resonance imaging-guided focused ultrasound unilateral pallidotomy for Parkinson's disease. <i>Neurology and Clinical Neuroscience</i> , 2021 , 9, 73-76	0.3	1
61	The effect of Subthalamic nucleus deep brain stimulation on verb and noun naming in Turkish-Speaking Parkinson's disease patients. <i>Brain and Language</i> , 2021 , 212, 104865	2.9	0
60	The Great Indian Apomorphine Story: Challenges and Its Usage in Parkinson's Disease in the Indian Context. <i>Neurology India</i> , 2021 , 69, 137-139	0.7	

59	Analysis of Parkinson's disease movement disorder by M E R with S T N Deep Brain Stimulations. <i>IP Indian Journal of Neurosciences</i> , 2021 , 7, 76-82	0.8	1
58	Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine. <i>Experimental Neurology</i> , 2021 , 340, 113670	5.7	5
57	Parkinson's Disease An Introduction. <i>Series in Bioengineering</i> , 2022 , 1-24	0.7	1
56	A flexible bioelectrode based on IrO ₂ -coated metallized polypropylene micromembrane. <i>Ceramics International</i> , 2021 ,	5.1	2
55	The role of neuroimaging in Parkinson's disease. <i>Journal of Neurochemistry</i> , 2021 , 159, 660-689	6	4
54	Synaptic Dysfunction in Parkinson's Disease: From Protein Misfolding to Functional Alterations. 2011 , 257-267		0
53	Stereotactic Radiosurgery for Movement Disorders. 2015 , 671-679		1
52	Pallidotomy for Parkinson's Disease. 2009 , 1539-1548		2
51	Parkinson Disease. 2008 , 761-765		1
50	Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. <i>Neurologia</i> , 2019 , 34, 143-152	1.4	15
49	PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. <i>Journal of Clinical Investigation</i> , 2012 , 122, 3977-89	15.9	100
48	Unbiased and mobile gait analysis detects motor impairment in Parkinson's disease. <i>PLoS ONE</i> , 2013 , 8, e56956	3.7	135
47	Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2013 , 8, e69738	3.7	22
46	Feasibility of large-scale deployment of multiple wearable sensors in Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0189161	3.7	74
45	Pharmacological Treatment in Parkinson's Disease. <i>Journal of the Korean Neurological Association</i> , 2019 , 37, 335-344	0.1	5
44	Large-Scale Wearable Sensor Deployment in Parkinson's Patients: The Parkinson@Home Study Protocol. <i>JMIR Research Protocols</i> , 2016 , 5, e172	2	34
43	Cellular models, genomic technologies and clinical practice: a synthesis of knowledge for the study of the mechanisms, diagnostics and treatment of Parkinson's disease. <i>Genes and Cells</i> , 2017 , XII,	1.4	3
42	Amantadine and anticholinergics. 2013 , 373-388		2

41	Parkinson disease: A summary of recent evidence-based medicine reviews. <i>Mental Health Clinician</i> , 2012 , 2, 25-31	1.6	2
40	Interface Modeling and Analysis of Interphase-Delay Induced Charge Imbalance in Neural Stimulator Design. <i>Communications in Computer and Information Science</i> , 2021 , 359-368	0.3	
39	Pharmacotherapy in Parkinson Disease : Its Advantages and Limitations(Parkinson Disease). <i>Japanese Journal of Neurosurgery</i> , 2006 , 15, 734-740	0	
38	Involuntary Movement Disorders. 2007 , 401-464		
37	Parkinson's Disease. 199-220		
36	Deep Brain Stimulation in Atypical Parkinsonism. 2008 , 291-303		
35	Trastornos de movimientos involuntarios. 2008 , 407-452		0
34	Parkinson's Disease. 2009 , 1044-1054		
33	Parkinson's Disease. 159-165		
32	Neurology. 2012 , 959-999		0
31	Dyskinesias in Parkinsonian Syndromes. 297-310		
30	Postsurgical Behavioral Changes. 2013 , 91-117		
29	Basal ganglia disorders. 2013 , 601-630		
28	P. 2013 , 784-929		
27	Sleep dysfunction. 2013 , 120-143		
26	Dopaminergic Neurons in Parkinson's Disease. 2014 , 753-788		1
25	Importância dos Agonistas Dopaminérgicos nas Fases Inicial e Avançada da Doença de Parkinson. <i>Revista Neurociencias</i> , 2006 , 14, 161-165	0	
24	Alpha-Dihydroergocryptine vs. Pramipexole as Adjunct Symptomatic Treatment of Idiopathic Parkinson's Disease. <i>Advances in Parkinson's Disease</i> , 2015 , 04, 1-8	0.2	

23	Biomimetic Materials: Polymeric Substrates for Axonal Regeneration. 913-931		
22	Movement Disorders and Motor Cortex Stimulation. 2016 , 189-207		
21	Rational and Methodology for the Appraisal of Clinical Trials in Movement Disorders. 2017 , 49-58		
20	Comparative examination of levodopa pharmacokinetics during simultaneous administration with lactoferrin in healthy subjects and the relationship between lipids and COMT inhibitory activity. <i>Nutritional Neuroscience</i> , 2020 , 1-10	3.6	
19	Spectral Signatures of L-DOPA-Induced Dyskinesia Depend on L-DOPA Dose and are Suppressed by Ketamine.		
18	Parkinsonian Drugs: Guidelines for Japan. 2020 , 1-29		
17	Continuous levodopa for advanced Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 335-48	3.1	21
16	Parkinson's disease. <i>Clinical Evidence</i> , 2007 , 2007,		
15	Treatment in late Parkinson's disease. <i>Annals of Indian Academy of Neurology</i> , 2011 , 14, S11-3	0.9	
14	Analysis of MER with subthalamic nucleus stimulations with deep brain stimulation. <i>IP Indian Journal of Neurosciences</i> , 2022 , 8, 64-68	0.8	
13	Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019.. <i>Frontiers in Public Health</i> , 2021 , 9, 776847	6	18
12	Psychosis in Parkinson's Disease: Looking Beyond Dopaminergic Treatments. <i>Current Pharmaceutical Design</i> , 2022 , 28,	3.3	
11	Clozapine Use in a Movement Disorder Clinic. <i>Clinical Neuropharmacology</i> , Publish Ahead of Print,	1.4	0
10	Parkinson's Disease: Neurochemistry and Pharmacological Treatment. 2022 , 145-167		
9	Machine Learning Smart System for Parkinson Disease Classification Using the Voice as a Biomarker. 2022 , 28, 210-221		0
8	Recent advances in dopamine D 2 receptor ligands in the treatment of neuropsychiatric disorders.		1
7	Parkinsonian Drugs: Guidelines for Japan. 2022 , 3051-3078		0
6	Comparative efficacy of transcranial magnetic stimulation on different targets in Parkinson's disease: A Bayesian network meta-analysis. 14,		0

- 5 Pros and Cons of Ablation for Functional Neurosurgery in the Neurostimulation Age. **2023**, 34, 291-299 ○
- 4 Anticipatory Postural Adjustments and Compensatory Postural Responses to Multidirectional Perturbations—Effects of Medication and Subthalamic Nucleus Deep Brain Stimulation in Parkinson— Disease. **2023**, 13, 454 ○
- 3 Confusion of Evidence-Based Reviews and Guidelines. **2023**, 38, 511-513 ○
- 2 Confusion of evidence-based reviews and guidelines. ○
- 1 Clinical benefit of MAO-B and COMT inhibition in Parkinson— disease: practical considerations. ○